Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048956 | 1.00 | HIF1A (0.75) | HIF1APNPLMNATP53HTT | |
| SCHEMBL23982423 | 1.00 | HIF1A (0.75) | HIF1APNPLMNATP53HTT | |
| SCHEMBL17612282 | 1.00 | HIF1A (0.75) | HIF1APNPLMNATP53HTT | |
| SCHEMBL2408903 | 1.00 | HIF1A (0.75) | HIF1APNPLMNATP53HTT | |
| SCHEMBL14440926 | 0.92 | HIF1A (0.64) | HIF1ASMN1; SMN2 | |
| Deoxyinosine SCHEMBL2000526 | 0.86 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL324457 | 0.86 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL5982293 | 0.86 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL24307 | 0.86 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL7191121 | 0.86 | HIF1A (0.73) | HIF1APNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4388114-A1 | CELL-TO-CELL DELIVERY OF RNA CIRCUITS | California Institute of Technology (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2024124190-A1 | ENGINEERED MICROORGANISMS FOR DELIVERY OF THERAPEUTIC AGENTS | MICROBIAL MACHINES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4370686-A1 | STOICHIOMETRIC EXPRESSION OF MESSENGER POLYCISTRONS | California Institute of Technology (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2024081912-A1 | PROTEIN-BASED SIGNAL AMPLIFICATION | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-04-18 | — | — | WO | claimed |
| US-20240018513-A1 | SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION | FRED HUTCHINSON CANCER CENTER (US) | 2024-01-18 | — | — | US | claimed |
| EP-4305179-A2 | ACOUSTIC REMOTE CONTROL OF MICROBIAL IMMUNOTHERAPY | California Institute of Technology (US) | 2024-01-17 | — | — | EP | claimed |
| WO-2024011146-A1 | A SYNTHETIC PROTEIN-LEVEL NEURAL NETWORK IN MAMMALIAN CELLS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-01-11 | — | — | WO | claimed |
| EP-4232577-A1 | SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION | Fred Hutchinson Cancer Center (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2023070134-A2 | SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION | FRED HUTCHINSON CANCER CENTER (US) | 2023-04-27 | — | — | WO | claimed |
| US-20230103980-A1 | THERMAL STATE SWITCHES IN MACROPHAGES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-04-06 | — | — | US | claimed |
| US-7820184-B2 | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders | GENELUX CORPORATION (US) | 2010-10-26 | — | — | US | claimed |
| US-7662398-B2 | anticancer treatment by administering a recombinant vaccina virus of a modified TK thymidine kinase and hemagglutinin gene; virus does not accumulate to toxic levels in non-targeted organs; kits | GENELUX CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| US-7588771-B2 | Microorganisms for therapy | GENELUX CORPORATION (US) | 2009-09-15 | — | — | US | claimed |
| US-20090180987-A1 | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders | GENELUX CORPORATION | 2009-07-16 | — | — | US | claimed |
| EP-2028270-A2 | Modified recombinant vaccina viruses and uses thereof | Genelux Corporation (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1644492-B1 | MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF | GENELUX CORP (US) | 2009-01-07 | — | — | EP | claimed |
| US-20070025981-A1 | anticancer treatment by administering a recombinant vaccina virus of a modified TK thymidine kinase and hemagglutinin gene; virus does not accumulate to toxic levels in non-targeted organs; kits | GENELUX CORPORATION | 2007-02-01 | — | — | US | claimed |
| US-20060051370-A1 | anticancer treatment by administering a recombinant vaccina virus of a modified TK thymidine kinase and HA hemagglutinin gene; virus does not accumulate to toxic levels in non-targeted organs | GENELUX CORPORATION | 2006-03-09 | — | — | US | claimed |
| US-5902740-A | Process for the decontamination of cell cultures containing mycoplasmas | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-05-11 | — | — | US | claimed |
| US-4387161-A | INCUBATION WITH 6-METHYLPURINE DEOXYRIBOSIDE; ANTIGROWTH AGENTS; CYTOLYSIS | INSTITUTE FOR MEDICAL RESEARCH (US) | 1983-06-07 | — | — | US | claimed |